GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Intensity Therapeutics Inc (NAS:INTS) » Definitions » Net-Net Working Capital

Intensity Therapeutics (Intensity Therapeutics) Net-Net Working Capital : $0.57 (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Intensity Therapeutics Net-Net Working Capital?

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.

Intensity Therapeutics's Net-Net Working Capital for the quarter that ended in Mar. 2024 was $0.57.

The industry rank for Intensity Therapeutics's Net-Net Working Capital or its related term are showing as below:

INTS's Price-to-Net-Net-Working-Capital is ranked worse than
73.8% of 920 companies
in the Biotechnology industry
Industry Median: 3.9 vs INTS: 8.61

Intensity Therapeutics Net-Net Working Capital Historical Data

The historical data trend for Intensity Therapeutics's Net-Net Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intensity Therapeutics Net-Net Working Capital Chart

Intensity Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Net-Net Working Capital
-0.17 -0.13 -0.71 -1.19 0.78

Intensity Therapeutics Quarterly Data
Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net-Net Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.24 -0.23 1.08 0.78 0.57

Competitive Comparison of Intensity Therapeutics's Net-Net Working Capital

For the Biotechnology subindustry, Intensity Therapeutics's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Intensity Therapeutics's Price-to-Net-Net-Working-Capital Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Intensity Therapeutics's Price-to-Net-Net-Working-Capital distribution charts can be found below:

* The bar in red indicates where Intensity Therapeutics's Price-to-Net-Net-Working-Capital falls into.



Intensity Therapeutics Net-Net Working Capital Calculation

Intensity Therapeutics's Net-Net Working Capital (NNWC) per share for the fiscal year that ended in Dec. 2023 is calculated as

Net-Net Working Capital(A: Dec. 2023 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(14.776+0.75 * 0+0.5 * 0-4.133
-0-0)/13.7094
=0.78

Intensity Therapeutics's Net-Net Working Capital (NNWC) per share for the quarter that ended in Mar. 2024 is calculated as

Net-Net Working Capital(Q: Mar. 2024 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(10.497+0.75 * 0+0.5 * 0-2.686
-0-0)/13.7119
=0.57

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.

In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

This is a conservative way of estimating the company's value.


Intensity Therapeutics  (NAS:INTS) Net-Net Working Capital Explanation

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.


Intensity Therapeutics Net-Net Working Capital Related Terms

Thank you for viewing the detailed overview of Intensity Therapeutics's Net-Net Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Intensity Therapeutics (Intensity Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
61 Wilton Road, 3rd Floor, Westport, CT, USA, 06880
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors.
Executives
Emer Leahy director 1111 LINCOLN ROAD, SUITE 500, MIAMI BEACH FL 33139
Daniel Donovan director 712 VISTA BLVD #305, WACONIA MN 55387
James M Ahlers officer: Executive VP of CF 2000 POWELL STREET, SUITE 1640, EMERYVILLE CA 94608
Lewis H Bender director, 10 percent owner, officer: President and CEO 765 OLD SAW MILL RIVER RD, TARRYTOWN NY 10591
Mark A Goldberg director PERCEPTIVE INFORMATICS INC, 200 WEST STREET, WALTHAM MA 02451
John M Wesolowski officer: Interim CFO 61 WILTON ROAD, 3RD FLOOR, WESTPORT CT 06880

Intensity Therapeutics (Intensity Therapeutics) Headlines

From GuruFocus